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Background: Longitudinal data on the impact of treatment on quality of life (QoL) in advanced 
non-small cell lung cancer (NSCLC) are limited. In this palliative setting, treatment that does 
not deteriorate QoL is key. Here we report longitudinal QoL in patients with squamous NSCLC, 
receiving ≤4 cycles of nab-paclitaxel/carboplatin combination chemotherapy.
Methods: Patients received nab-paclitaxel 100 mg/m2 days 1, 8, 15 + carboplatin area under 
the curve 6 mg•min/mL day 1 (q3w) for four cycles. QoL was assessed by the Lung Cancer 
Symptom Scale (LCSS) and Euro-QoL-5 Dimensions-5 Levels (EQ-5D-5L) at baseline and 
each cycle (day 1). 
Results: Two-hundred and six lesion-response-evaluable patients completed baseline + ≥1 
postbaseline QoL assessment and were QoL evaluable. LCSS average total score and symptom 
burden index improved from baseline throughout four cycles. In the LCSS pulmonary symptoms 
score, 46% of patients reported clinically meaningful improvement (≥10 mm visual analog scale) 
from baseline. Individual EQ-5D-5L dimensions remained stable/improved in ≥83% of patients; 
≈33% reported complete resolution of baseline problems at least once during four cycles. Gener-
ally, responders (unconfirmed complete/partial response) had higher scores vs nonresponders.
Conclusion: In patients with squamous NSCLC, four cycles of nab-paclitaxel/carboplatin 
demonstrated clinically meaningful QoL improvements, with greater benefits in responders 
vs nonresponders. 
Keywords: nab-paclitaxel, non-small cell lung cancer, quality of life, response, squamous
Introduction
Patients with advanced non-small cell lung cancer (NSCLC) often experience a high 
symptom burden and a significantly deteriorated quality of life (QoL).1–3 In a real-
world cross-sectional analysis of patients receiving treatment for advanced NSCLC 
(N = 450), all patients reported experiencing fatigue, and most experienced loss of 
appetite, shortness of breath, cough, hemoptysis, and pain.4 These data indicate that 
in addition to prolonging survival, identifying a first-line treatment regimen that does 
not deteriorate physical well-being but instead maintains or improves symptom burden 
and/or QoL, is important for disease and treatment outcomes. 
Despite recent treatment advances, chemotherapy remains the first-line standard 
of care for the majority of patients with advanced NSCLC (without a high level of 
PD-L1 expression), including those with squamous histology.5,6 However, there is a 
paucity of longitudinal QoL data from patients with advanced NSCLC receiving che-
motherapy, and the data that do exist are often contradictory. Some studies have found 
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that platinum-based chemotherapy improves QoL,7 while 
others have found no improvement in QoL when compared 
with other treatments such as targeted agents.8–10 Prospec-
tive QoL data from clinical trials are even more limited in 
patients with squamous NSCLC, as few trials have reported 
QoL outcomes by histology.
nab-Paclitaxel in combination with carboplatin is approved 
for the first-line treatment of locally advanced or metastatic 
NSCLC in patients who are not candidates for curative surgery 
or radiation therapy, based on a favorable risk-benefit profile 
compared with paclitaxel plus carboplatin in a randomized 
Phase III trial.11,12 Compared with paclitaxel plus carboplatin, 
nab-paclitaxel plus carboplatin demonstrated a significant 
increase in the primary endpoint of overall response rate (ORR) 
(33% vs 25%, P = 0.005) in the intent-to-treat population. A 
subset analysis of patients with squamous histology demon-
strated a 68% improvement in ORR with nab-paclitaxel plus 
carboplatin compared with paclitaxel plus carboplatin (41% 
vs 24%; P < 0.001).12 The nab-paclitaxel plus carboplatin regi-
men was also well tolerated across histologies, as evidenced 
by the safety profile and patient-reported taxane-related 
symptom improvements.12–14 Although significant reductions 
in taxane-related symptoms such as neuropathy and neuro-
pathic pain were reported with nab-paclitaxel plus carboplatin 
compared with paclitaxel plus carboplatin, it should be noted 
that improvements in these taxane-related symptoms may not 
reflect improvements in overall patient QoL.14 This further 
underscores the need to assess the impact of this regimen on 
QoL in a prospective clinical trial.
The Phase III ABOUND.sqm trial is investigating first-
line nab-paclitaxel plus carboplatin treatment followed 
by nab-paclitaxel with or without best supportive care as 
maintenance treatment in patients with advanced squamous 
NSCLC. The objective of this analysis was to evaluate the 
impact of four cycles of nab-paclitaxel plus carboplatin on 
patient-reported symptoms and health-related QoL outcomes. 
Ethics approval and consent to 
participate
This study was conducted in accordance with the Declara-
tion of Helsinki and Good Clinical Practice Guidelines of 
the International Conference on Harmonisation. Informed 
consent was obtained from all patients prior to study entry. 
The study received approval from institutional review 
boards prior to commencement. The trial is registered at 
 ClinicalTrials.gov (NCT02027428).
The approving Institutional Review Boards/Ethics Com-
mittees were Bundesinstitut für Arzneimittel und Mediz-
inprodukte, Ethikkommission der Medizinischen Fakultät 
Heidelberg, Agenzia Italiana del Farmaco, Comitato Etico 
Campania Nord, Agencia Española de Medicamentos y 
Productos Sanitarios (AEMPS), CEIC Hospital Clinico San 
Carlos, Health Research Authority, Medicines and Healthcare 
Products Regulatory Agency, NRES Committee London 
Surrey Borders, and Quorum Review IRB.
Materials and methods
Study population
Patients with stage IIIB or IV, histologically or cytologically 
confirmed squamous NSCLC measurable by “Response 
Evaluation Criteria In Solid Tumors” (RECIST) version 
1.1 were enrolled in this study. Key eligibility require-
ments included ≥18 years of age, no prior chemotherapy 
for metastatic disease, Eastern Cooperative Oncology 
Group performance status of 0 or 1, and adequate hema-
tologic, renal, and liver function. Patients with active brain 
metastases or preexisting peripheral neuropathy grade ≥2 
were excluded.
Study design
The Phase III, randomized, open-label, multicenter 
ABOUND.sqm study is being conducted at ≈120 sites in the 
United States and the European Union. In the induction part, 
patients were treated with nab-paclitaxel  (ABRAXANE®, 
albumin-bound paclitaxel) 100 mg/m2 intravenously on 
days 1, 8, and 15 plus carboplatin area under the curve 
 6 mg•min/ mL intravenously on day 1, every 21 days. After 
completion of four cycles, patients without progression 
could continue to the maintenance part of the study in which 
they would be randomized 2:1 to receive nab-paclitaxel 
100 mg/ m2 intravenously on days 1 and 8 every 21 days 
plus best supportive care or best supportive care alone until 
disease progression. Randomization was stratified by disease 
stage before four cycles of treatment (IIIB vs IV), response at 
randomization (complete response/partial response [CR/PR] 
vs stable disease), and performance status at the end of the 
induction part (0 vs 1). The primary endpoint of the study is 
progression-free survival, which was measured from the time 
the patient was randomized at the start of the maintenance 
portion to the point of progression during the maintenance 
portion. Secondary endpoints include overall survival from 
randomization through the maintenance part, ORR during 
the induction and maintenance parts, and disease control rate 
over the entire study. Change in patient-reported QoL dur-
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QoL in squamous NSCLC with nab-P/C induction
QoL assessments
The Lung Cancer Symptom Scale (LCSS) and the Euro-
QoL-5 Dimensions-5 Levels (EQ-5D-5L) questionnaires 
were used to measure QoL (Figure S1). In this analysis, per 
protocol, patient-reported QoL was assessed using the LCSS 
and EQ-5D-5L during four cycles of treatment on day 1 of 
each cycle through the end of the induction phase (cycle 5 
day 1; prior to maintenance treatment). Patients completed 
the QoL self-assessments in the clinic using digital tablets.
The LCSS is a validated, disease-specific instrument 
completed by both patients and observers to measure QoL 
in patients with lung cancer.15 The patient version of the 
LCSS consists of eight individual questions about lung 
cancer symptoms (appetite, fatigue, dyspnea, cough, pain, 
hemoptysis, overall symptom severity, and normal activities) 
all measured during the past 24 hours, one global question 
on QoL, one average total score of the nine questions, and 
one mean score of the six questions on major lung cancer 
symptoms. Patients answer each question using a visual ana-
log scale (VAS) of 0 to 100 mm, where 0 = best and 100 = 
worst to indicate the intensity of a symptom. Figure S1 shows 
the components of the LCSS scores used in this analysis. 
The EQ-5D is a generic instrument designed for self-
completion that measures the patient’s health today and 
comprises the EQ-5D and a VAS for overall QoL.16,17 The 
EQ-5D includes questions on five dimensions of health 
(mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression). The answers to each EQ-5D-5L ques-
tion are based on five qualitative levels (no problems, slight 
problems, moderate problems, severe problems, or unable to 
perform the activity). The EQ-5D-5L global index combines 
each of the five dimensions as a measure of the patient’s 
global health state. The VAS records the patient’s self-rated 
status for overall QoL based on a scale of 0 to 100 where 
0 = worst and 100 = best. 
Lesion response evaluation
Patients had a radiographic evaluation of lesions at the end 
of cycles 2 and 4. Patients with a CR or PR (by RECIST 
version 1.1 during the induction phase per the investiga-
tor), or those who experienced progressive disease in either 
evaluation or stable disease in both evaluations, or those who 
discontinued before or by the end of cycle 4, were considered 
lesion-response-evaluable. 
Statistical analysis
This analysis included patients who were lesion-response-
evaluable during the induction part of the study with available 
QoL data from baseline and ≥1 postbaseline visit. A clinically 
meaningful improvement in LCSS or EQ-5D VAS-scaled 
questions was defined as ≥1 postbaseline score for a given 
time point that was ≥10 mm higher than the baseline score.3 
For statistical analysis purposes, all scales were aligned so 
that a positive change from baseline indicated improvement. 
Changes from baseline LCSS and EQ-5D VAS-scaled items 
were described by descriptive statistics. The percentages 
of patients who had a clinically meaningful response, of 
patients who maintained or improved from baseline in the 5 
EQ-5D-5L dimensions, and of patients who had complete 
resolution of a baseline problem at least once during four 
cycles of treatment are summarized. 
Results
Patients
Of the 540 patients planned for enrollment into the induc-
tion part of the study, 284 patients had been treated as of 
September 6, 2016. Of these 284 patients, 246 patients were 
lesion-response-evaluable. Of the lesion-response-evaluable 
patients, the median age was 68 years, and 41% of patients 
were aged ≥70 years. The majority (67%) of patients had a 
baseline Eastern Cooperative Oncology Group performance 
status of 1 (Table 1). 
QoL compliance
Of the 284 patients treated in the induction part, 251 were 
treated in cycle ≥2 and were eligible to complete ≥1 post-
baseline QoL assessment. Of these, 223 (89%) completed 
baseline and ≥1 postbaseline assessments. 
QoL results
LCSS
In total, 206 patients were lesion-response-evaluable with 
available QoL data from baseline and ≥1 postbaseline visit 
and were included in the LCSS analysis. In general, symp-
tom burden decreased and QoL improved during four cycles 
of treatment with nab-paclitaxel plus carboplatin. Positive 
changes from baseline were observed in several LCSS 
symptom scores, including cough, appetite, and pain. For 
the LCSS average total score, improvement from baseline 
peaked on cycle 2 day 1 and remained stable throughout the 
rest of the induction phase (Figure 1A). A similar trend was 
noted for the average symptom burden index (Figure 1B). 
For the lung cancer symptom score that rated the severity of 
disease-specific symptoms, improvements from baseline were 
observed during each of the four cycles of nab-paclitaxel plus 
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score remained generally stable with respect to baseline 
scores throughout the induction phase, as did the changes 
in the 3-item index scores (Figure 2A and B). Overall, 46% 
of patients achieved a clinically meaningful improvement 
(≥10 mm) from baseline in the composite score of pulmonary 
symptoms during the induction phase. Clinically meaningful 
improvements in the individual items of cough, shortness of 
breath, and hemoptysis were also reported in 58%, 49%, and 
16% of patients, respectively. 
EQ-5D-5L
Two-hundred and six patients who were lesion-response-
evaluable with available QoL data from baseline and ≥1 
postbaseline visit were also included in the EQ-5D-5L 
analysis. The majority of patients experienced stability or 
improvement from baseline in individual EQ-5D-5L items, 
including self-care (91%), mobility (88%), anxiety/depres-
sion (88%), pain/discomfort (85%), and usual activities 
(83%) (Table 2). In patients reporting problems at baseline, 
complete resolution from baseline at least once during four 
cycles of treatment was reported in 30% to 50% of patients 
in individual EQ-5D-5L dimensions. 
LCSS and EQ-5D-5L by lesion response 
Overall, of lesion-evaluable patients who completed baseline 
and ≥1 postbaseline QoL assessment, 110 were responders 
(CR/PR), and 96 were nonresponders. Responders had higher 
QoL scores compared with the overall population and nonre-
sponders. LCSS average total score, average symptom burden 
index, and lung cancer symptom scores were improved from 
baseline in responders and were generally stable with respect 
to baseline in nonresponders (Figure 1A–C). Overall, 56% of 
responders and 33% of nonresponders achieved a clinically 
meaningful improvement in the composite score of pulmo-
nary symptoms. 
Across all EQ-5D-5L dimensions, stabilization or 
improvements in QoL scores were more pronounced in 
responders vs nonresponders and vs the overall population 
(Table 2). The percentage of responders reporting complete 
resolution at least once was nearly double that of nonre-
sponders in the individual dimensions of usual activities 
(39% vs 21%), pain/discomfort (44% vs 27%), and anxiety/
depression (59% vs 31%). 
Discussion
These are the first published data of QoL outcomes with 
nab-paclitaxel plus carboplatin treatment in patients with 
advanced NSCLC. In this interim analysis of the Phase III 
ABOUND.sqm trial, treatment with four cycles of first-line 
nab-paclitaxel plus carboplatin resulted in maintenance of 
or improvement in QoL in patients with advanced squamous 
NSCLC. Clinically meaningful improvements from baseline 
were observed in composite LCSS lung cancer pulmonary 
symptoms in 46% of patients. In addition, several EQ-
5D-5L components stabilized or improved in the majority 
of patients, and approximately one third of patients reported 
complete resolution of a problem reported at baseline at least 
once during four cycles of nab-paclitaxel plus carboplatin. 
Improvement in QoL was more pronounced in responders 
compared with the overall population and nonresponders.
nab-Paclitaxel plus carboplatin is a recommended regi-
men for the first-line treatment of patients with both squamous 
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QoL in squamous NSCLC with nab-P/C induction
Figure 1 Lung Cancer Symptom Scale average total (A), average symptom burden index (B), and lung cancer symptom (C) scores.
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and nonsquamous advanced NSCLC, based on results of the 
registrational Phase III trial vs paclitaxel plus carboplatin.5,6,12 
In the Phase III registrational trial, significant improvements 
in ORR were reported for nab-paclitaxel plus carboplatin vs 
paclitaxel plus carboplatin for the intent-to-treat population, 
as well for the subset of patients with squamous histology. 
The regimen was well tolerated with significantly less grade 
≥3 neuropathy and arthralgia but more thrombocytopenia and 
Figure 2 Lung Cancer Symptom Scale global (A) and 3-item index (B) scores. 
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Table 2 EQ-5D-5L maintenance/improvement and complete resolution of problems in each dimension
EQ-5D-5L
Dimension Maintenance/improvement  
at least once during treatment, n/N (%)
Complete resolution  
at least once during treatment, n/N (%)a
Responders Nonresponders Overall Responders Nonresponders Overall
Mobility 104/110 (95) 78/96 (81) 182/206 (88) 19/52 (37) 17/51 (33) 36/103 (35)
Self-care 107/110 (97) 81/96 (84) 188/206 (91) 14/24 (58) 10/24 (42) 24/48 (50)
Usual activities 95/110 (86) 75/96 (78) 170/206 (83) 27/70 (39) 13/63 (21) 40/133 (30)
Pain/discomfort 100/110 (91) 76/96 (79) 176/206 (85) 36/82 (44) 17/63 (27) 53/145 (37)
Anxiety/depression 106/110 (96) 75/96 (78) 181/206 (88) 39/66 (59) 15/49 (31) 54/115 (47)
Note: aIn patients reporting problems at baseline.
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QoL in squamous NSCLC with nab-P/C induction
anemia observed compared with paclitaxel plus carboplatin.13 
Additionally, significant improvements in taxane-related 
symptoms, such as neuropathy and neuropathic pain, were 
reported with nab-paclitaxel plus carboplatin compared with 
paclitaxel plus carboplatin, regardless of histology.14 The 
improvements in QoL reported during four cycles of nab-
paclitaxel plus carboplatin treatment from the ABOUND.
sqm study corroborate these findings and further expand 
the understanding of the overall clinical benefit of the nab-
paclitaxel plus carboplatin regimen in patients with advanced 
NSCLC.12,14,18
Given the substantial symptom distress (cough, pain, 
loss of appetite, and hemoptysis) associated with both lung 
cancer and its treatment, QoL data are becoming an important 
tool for chemotherapy decision making.19–23 The high tumor 
burden in many patients with advanced NSCLC can result in 
a negative impact on QoL and worsen disease-related symp-
toms.24,25 Patients with squamous histology represent nearly 
one third of all patients with NSCLC; thus, analyses of QoL 
are of great significance, as the location, size, and cavitating 
nature of many squamous NSCLC tumors may increase the 
symptomatic burden compared with other histologies.25–27 
However, there remains a lack of prospective clinical trial 
data of the impact of chemotherapy on symptoms/QoL, 
particularly for platinum-doublet therapy in patient subsets 
with unmet needs, such as squamous NSCLC. The current 
analysis adds to the limited body of knowledge on QoL data 
in patients with squamous NSCLC treated with first-line 
platinum doublets, and indicates that four cycles of nab-
paclitaxel plus carboplatin treatment maintain or improve 
QoL in this patient population. 
In addition to symptoms, patient health status (i.e., mobil-
ity, anxiety/depression, and usual activities) can be impacted 
by disease and treatment. For example, in a cross-sectional 
study of 126 newly diagnosed patients with advanced NSCLC 
treated with docetaxel plus cisplatin, 38% reported depression 
at baseline.28 QoL significantly declined with treatment in 
these patients, relative to those who did not report depression 
at baseline. In addition, depression was associated with worse 
survival. Another study assessed QoL changes in patients 
with advanced NSCLC (N = 39) and found significant 
declines from baseline in physical and social functioning, 
among other QoL areas, during treatment with platinum-
doublet chemotherapy.29 In the current study evaluating 
nab-paclitaxel plus carboplatin treatment, some health status 
issues (individual EQ-5D-5L dimensions of mobility, anxiety/
depression, usual activities, pain/discomfort, and self-care) 
were maintained or improved in the majority of patients, with 
≈30% reporting complete resolution from baseline at least 
once during treatment.
Understanding the impact of response on QoL is also 
important, as tumor shrinkage associated with tumor response 
could alleviate symptoms that are related to tumor size.30,31 In 
the current study, QoL improvements measured by both the 
LCSS and the EQ-5D-5L were more pronounced in patients 
responding (CR/PR) to nab-paclitaxel plus carboplatin dur-
ing the induction phase of the study vs those not responding. 
In line with these findings, in a retrospective analysis of 
patient-reported health-related QoL data from a large Phase 
III study in advanced NSCLC (N = 488), patients with a 
CR/PR or stable disease after treatment with pemetrexed 
or docetaxel demonstrated statistically significant mean 
maximum improvements from baseline in all LCSS items 
except for hemoptysis.30 In contrast, mean LCSS scores 
for each individual item worsened for patients with disease 
progression. Although the response data in this analysis are 
preliminary, they provide some insight on the clinical benefit 
of nab-paclitaxel plus carboplatin in patients with advanced 
squamous NSCLC. 
EQ-5D and LCSS are validated tools for QoL measure-
ments, yet they both have limitations that have been discussed 
at length elsewhere.15,16,32 Limitations of this analysis include 
QoL assessment only during the induction phase, the homo-
geneous patient subset with respect to race (mostly white), 
and the limited patient number in some cycles. In addition, 
differences in use of supportive care for the treatment of 
pain may have diluted the results of the EQ-5D-5L pain/
discomfort category. Further analyses including data from the 
maintenance setting are forthcoming and may help strengthen 
future QoL analyses from this study.
Conclusion
These results from the Phase III ABOUND.sqm trial dem-
onstrate that four cycles of first-line nab-paclitaxel plus 
carboplatin improved or maintained QoL in patients with 
advanced squamous NSCLC. In addition, patients with a 
tumor response (CR/PR) appeared to have better QoL out-
comes than those without a response. These findings in con-
junction with those reported from the Phase III registrational 
trial support nab-paclitaxel plus carboplatin as a treatment 
choice for this difficult-to-treat patient population. Moreover, 
it appears that declining QoL observed in nonresponders may 
be related to symptoms of disease progression. Therefore, 
given the importance of response during induction therapy, 
the impact of four cycles of nab-paclitaxel combination 
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Figure S1 Components of the LCSS used in this analysis. 
Note: a The 3-item index is a sum of the listed items and is scaled from 0 to 300 mm.
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